Apellis Pharmaceuticals, Inc. (APLS) News
Filter APLS News Items
APLS News Results
|Loading, please wait...|
APLS News Highlights
- APLS's 30 day story count now stands at 8.
- Over the past 26 days, the trend for APLS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about APLS are DRUG and NVAX.
Latest APLS News From Around the Web
Below are the latest news stories about APELLIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate APLS as an investment opportunity.
Why Is Novavax (NVAX) Down 14.7% Since Last Earnings Report?
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
WALTHAM, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023, at 9:20 a.m. PT. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to five new employees with a grant date of June 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company
Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails
Apellis' (APLS) phase II MERIDIAN study on pegcetacoplan for the treatment of amyotrophic lateral sclerosis fails to meet primary and key secondary endpoints.
Apellis stops pursuing ALS drug approval after trial failure
Apellis Pharmaceuticals Inc. is stopping work on a drug for amyotrophic lateral sclerosis, or ALS, after it failed in a midstage trial.
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
WALTHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Phase 2 MERIDIAN study investigating systemic pegcetacoplan for the treatment of amyotrophic lateral sclerosis (ALS) did not meet its primary endpoint of the Combined Assessment of Function and Survival (CAFS) rank score at Week 52. The study also did not meet key secondary efficacy endpoints. Systemic pegcetacoplan was well tolerated in the study, and the data were consistent w
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.
Analysts' Revenue Estimates For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Are Surging Higher
Celebrations may be in order for Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shareholders, with the analysts...
Apellis Pharmaceuticals First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Apellis Pharmaceuticals ( NASDAQ:APLS ) First Quarter 2023 Results Key Financial Results Revenue: US$44.8m (up 212...
Apellis Obliterates Sales Expectations; Is A Takeover In The Cards?
Apellis' new eye drug, Syfovre, crushed expectations in its first quarter post launch, sending APLS stock to a record high.